WuXi Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	9,214	8,279	9,670	6,395	9,003
Short-Term Investments	5,587	1,907	340	304.47	1,148
Trading Asset Securities	931.98	523.59	1,234	2,015	975.58
Cash & Short-Term Investments	15,733	10,710	11,243	8,714	11,126
Cash Growth	46.90%	-4.75%	29.02%	-21.68%	31.20%
Accounts Receivable	7,800	5,735	6,184	5,158	3,273
Other Receivables	1,096	639.86	490.64	616.59	908.05
Receivables	8,896	6,374	6,675	5,775	4,181
Inventory	1,381	1,522	1,766	2,281	1,687
Other Current Assets	2,126	4,967	1,514	1,700	2,535
Total Current Assets	28,135	23,573	21,198	18,470	19,530
Property, Plant & Equipment	29,754	28,435	29,939	25,916	19,756
Long-Term Investments	3,203	2,400	2,934	2,709	2,203
Goodwill	1,530	1,530	1,530	1,530	1,530
Other Intangible Assets	467.2	442.37	511.83	548.78	600.65
Long-Term Accounts Receivable	50.77	85.67	165.5	109.17	124.49
Long-Term Deferred Tax Assets	500.89	444.32	235.78	222.57	220.79
Other Long-Term Assets	55.79	66.78	60.69	58.88	68.42
Total Assets	63,697	56,977	56,576	49,564	44,033
Accounts Payable	1,092	747.15	833.27	1,221	617.78
Accrued Expenses	1,159	828.19	805.04	975.29	852.59
Current Portion of Long-Term Debt	873.52	2,435	576.33	1,321	2,122
Current Portion of Leases	381.95	183.7	154.98	149.06	103.56
Current Income Taxes Payable	791.29	647.66	618.88	773.83	557.73
Current Unearned Revenue	2,788	2,356	3,090	3,379	1,734
Other Current Liabilities	1,223	1,423	1,558	1,499	2,268
Total Current Liabilities	8,308	8,621	7,636	9,319	8,256
Long-Term Debt	169.38	200.9	1,571	1,462	640.51
Long-Term Leases	1,679	2,120	2,259	1,490	1,429
Long-Term Unearned Revenue	341.08	460.47	969.23	949.46	876.73
Long-Term Deferred Tax Liabilities	139.02	97.31	122.54	132.08	124.21
Other Long-Term Liabilities	21.14	-	-	-	-
Total Liabilities	10,657	11,500	12,558	13,351	11,326
Common Stock	0.23	0.23	0.24	0.23	0.24
Additional Paid-In Capital	-	23,532	24,489	22,102	27,044
Retained Earnings	-	18,334	14,978	11,578	7,158
Treasury Stock	-	-	-916.92	-	-2,517
Comprehensive Income & Other	47,248	-46.54	1,782	1,367	593.13
Total Common Equity	47,249	41,819	40,332	35,047	32,279
Minority Interest	5,791	3,658	3,686	1,166	427.57
Shareholders' Equity	53,039	45,478	44,018	36,213	32,706
Total Liabilities & Equity	63,697	56,977	56,576	49,564	44,033
Total Debt	3,104	4,940	4,561	4,422	4,295
Net Cash (Debt)	12,629	5,770	6,682	4,293	6,831
Net Cash Growth	118.87%	-13.65%	55.66%	-37.16%	32.68%
Net Cash Per Share	3.02	1.36	1.54	0.98	1.54
Filing Date Shares Outstanding	4,134	4,106	4,223	4,225	4,224
Total Common Shares Outstanding	4,134	4,106	4,223	4,225	4,224
Working Capital	19,828	14,952	13,562	9,151	11,274
Book Value Per Share	11.43	10.19	9.55	8.29	7.64
Tangible Book Value	45,252	39,847	38,290	32,969	30,148
Tangible Book Value Per Share	10.95	9.70	9.07	7.80	7.14
Land	-	7,701	6,195	2,114	2,097
Machinery	-	9,388	7,632	6,029	4,997
Construction In Progress	-	9,755	13,750	15,935	10,873
Leasehold Improvements	-	3,764	3,357	2,581	1,795
Order Backlog	165,767	135,033	-	-	86,376

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.